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Background A medical device containing the film-forming agent reticulated protein 
and a prebiotic mixture of vegetable oligo- and poly-sachharides has been developed, 
being recently received European approval as MED class III for the treatment of 
chronic/functional or recidivant diarrhea due to different causes including irritable 
bowel syndrome (IBS). In the present paper, we evaluated protein preparation 
containing these components in comparison with placebo in adult patients with 
diarrhea-predominant IBS. 
Methods In a randomized, placebo-controlled, double-blind, parallel group, multicentre, 
clinical trial, patients were randomly assigned to receive the combination of oligo- and 
poly-saccharides and reticulated protein and placebo (4 oral tablets/day during 56 days). 
Demographic, clinical and quality of life characteristics and presence and intensity of 
abdominal pain and flatulence (7-point Likert scale) were assessed at 3 study visits 
(baseline, at 28 and 56 days). Stools emissions were recorded in the diary card using the 
7-point Bristol Stool Scale.  
Results A total of 128 patients were randomized to receive either tablets containing the 
combination (n=63) or placebo (n=65). Treatment with oligo- and poly-saccharides and 
reticulated protein was safe and well tolerated. A significant improvement in symptoms 
across the study was observed in patients treated with oligo- and poly-saccharides and 




flatulence (p=0.0373). We also detected a statistically significant increase in the quality 
of life of patients receiving the active treatment from baseline to visit 3 (p<0.0001). 
Conclusions Treatment with oligo- and poly-saccharides and reticulated protein is safe, 





Irritable bowel syndrome (IBS) is the most frequently diagnosed functional 
gastrointestinal disorder in primary and secondary care (up to 50% of all office visits to 
gastroenterology clinics).1-4 It is characterized by abdominal discomfort, pain and 
changes in bowel habits, in the absence of an organic cause.1,2 Discomfort or abdominal 
pain relieved by defecation, associated with changes in stool form, is considered typical 
clinical manifestations in IBS.3,5-9 IBS is a problematic disorder resulting in impaired 
quality of life and high healthcare costs and high resources´ utilization,1-3,10 remaining a 
clinical challenge in the 21st century.3 
The pathogenesis of IBS, not yet completely understood, is complex and 
multifactorial and includes physiological, emotional, cognitive and behavioural 
pathways (biopsychosocial model), a number of which implicate a role for the 
gastrointestinal microbiota.1-3,11 Due to the heterogeneity of IBS, there is no standard or 
definitive treatment and the chronic use of drugs should be minimized as much as 
possible or even avoided.3 Symptoms can be controlled by non-pharmacologic 
management during variable time periods and eliminating some exacerbating factors 
such as certain drugs, stressor conditions or changes in dietary habits.3 In fact, the 





In this regard, since non-pharmacological options including film-forming agents and 
prebiotics could have a role in IBS, a medical device containing the film-forming agent 
reticulated protein and a prebiotic mixture of vegetable oligo- and poly-saccharides has 
been developed, being recently received European approval as MED class III for the 
treatment of chronic/functional or recidivant diarrhea due to different causes, including 
IBS. 
This combination represents a new non-pharmacological option for the treatment of 
IBS based on the combination of a mucosal protector, with film-forming properties to 
control diarrhea,13,14 and the prebiotic mixture of vegetable oligo- and poly-saccharides, 
which could have a role in the microbiota's composition, especially increase in 
bifidobacteria, that can be regarded as a marker of intestinal health.15,16 The present 
randomized, placebo-controlled, double-blind, parallel group, multicentre, clinical trial 
was performed to evaluate the safety and efficacy of tablets containing oligo- and poly-




The study protocol was approved by the Ethics Committee of Human Experimentation 
in Romania and procedures were in accordance with the ethical standards laid down in 




obtained from all subjects. Patients were recruited in different Romanian private offices 
of general practitioners (with the participation of 15 centres from Bucharest, Galati, 
Craiova and Gluj) in the context of their routine clinical practice.  
 
Study population and study design 
This randomized, placebo-controlled, double-blind, parallel group, multicentre, clinical 
trial was performed to evaluate the safety and efficacy of the active treatment (tablets 
containing a mixture of vegetable oligo- and poly-saccharides -750 mg-, reticulated 
protein -250 mg-, and the excipients corscarmellose sodium -133 mg- and magnesium 
stearate -17 mg-), in comparison with placebo (tablets containing corn starch, 
corscarmellose sodium and magnesium stearate) in adult patients with diarrhea-
predominant IBS, with good general health status (normal physical and analytical 
conditions). Potential participants were excluded if they had organic gastrointestinal 
diseases.  
The mixture of oligo- and poly-saccharides is manufactured by Beneo oralfi, GmbH 
(Germany) by the extraction from vegetable roots (chicory). 
Reticulated protein is manufactured by Laboratorios Argenol, SA (Spain) by the 
mixture of tannins and protein (gelatin)." 
The dose used in this clinical study is based on the results of previous preclinical studies 




Diarrhea-predominant IBS was diagnosed following Rome III criteria,2,17 according 
which recurrent abdominal pain or discomfort had to be present at least 3 days/month in 
the last 3 months, associated with two or more points: improvement with defecation, 
onset associated with a change in frequency of stools, onset associated with a change in 
form (appearance) of stool. In diarrhea-predominant IBS, the stool pattern includes 
loose (mushy) or watery stools (Bristol scale 6–7)18,19 ≥25% and hard or lumpy stool 
<25% in the absence of antidiarrheal or laxative use.2,17,20 
Subjects allocation to treatment group was determined by a computer generated 
randomization list, which was stratified by center. Double blinding procedures were 
applied during the whole period of the study.  
Patients were randomly assigned to receive the combination (Novintethical Pharma, 
SA) and placebo at a ratio of 1:1 in the form of oral tablets at a posology of 4 
tablets/day (2 before breakfast and 2 before dinner) during a period of 8 weeks (56 
days). 
The active and placebo tablets were manufactured by direct compression, following 
the processes of dispensing, mixing and packaging.  
After intake of tablets, the active substances of the product, a mixture of vegetable 
oligo- and poly-saccharides and reticulated protein, are no absorbed at the 





Study chronogram and workflow are shown in Figure 1a and Figure 1b, respectively. 
During the first enrolment visit, patients from the 2 groups were given a 56-day 
treatment (with the first dose being administered at the time of recruitment) and were 
instructed to fulfill a patient´s diary card to daily register the time of treatment intake, 
the severity and frequency of adverse events (AEs), the number and type of stool 
emissions and the use of rescue medication for IBS symptoms. At this visit, 
demographic and clinical characteristics were also recorded. 
During visit 1 and visit 3 (day 56), patients were interviewed using the IBS QoL 
questionnaire21 and physical examination and blood sampling for haematological and 
biochemical analysis were performed (Figure 1a). 
During visits 1, 2 (day 28) and 3, patients measured the presence and intensity of 
abdominal pain and flatulence in a 7-point Likert scale (7=very much better, 6=much 
better, 5=somewhat better, 4=same, 3=somewhat worse, 2=much worse, 1=very much 
worse) (Figure 1a). 
Stools emissions (including number of emissions/day) were recorded in the diary 
card and consistency of each stool was assessed using the 7-point Bristol Stool 
Scale.18,19 
At visit 3, patients returned the fulfilled diary card and the remaining medication and 




calculation of the percentage of patients who took all the recommended medication 
during the 56-day period.  
The IBS QoL questionnaire is a 34-item measure constructed specifically to assess 
the subjective well-being of patients with IBS, including eight dimensions (dysphoria, 
interference with activity, body image, health worry, food avoidance, social reaction, 
sexual dysfunction, and relationships). Each item is scored on a five-point scale (1=not 
at all, 5=a great deal). The summed total score is transformed to a zero to 100 scale 
ranging from zero (maximum quality of life) to 100 (minimum).21 In the version we 
used, higher scores on the IBS-QoL indicated poorer quality of life. This version has 
been used to assess quality of life of IBS patients in other published studies.22 
 
Primary variables 
The primary safety variable was the prevalence of AEs in the both groups of patients. 
The frequency, intensity and relationship with the studied product were recorded during 
the 3 study visits, together with significant changes in vital signs and analytical 
parameters. 
The primary efficacy variable was the rate of clinical remission at 4 and 8 weeks, 
defined as the disappearance of diarrhea, i.e. 2 or less nonwatery stools emissions per 






Sample size (n=130, n=65 in each group) was calculated to have a 80% of power to 
detect, with 95% probability, a non-inferiority margin difference between the group 
proportions of 0.1100. 
The comparison between the active and the placebo group on the clinical remission 
was performed using Fisher’s Exact test and by constructing a 95% Confidence 
Interval around the difference between the clinical remission rates showed by the active 
group and placebo group. 
Non-parametric analyses were carried out on the abdominal pain and flatulence 
parameters to test the presence of any significant difference between the improvement 
rates of treatment group vs placebo group. An independent sample t-test was used to 
compare the changes from baseline on the IBS QoL summed scores of the two groups. 
The difference between the frequency of AEs occurrence was assessed using Fisher´s 
Exact test and by constructing a 95% confidence intervals around the difference 
between the mean frequency of AEs occurrence in both groups. 
In all cases, p<0.05 were considered significant. According to CPMP/ICH/363/96 
and CPMP/EWP/482/99 guidelines, both two-sided (at 95% significance level) and one-
sided tests (at 97.5% significance level) were performed. Statistical analyses were 






A total of 130 Caucasian patients were recruited (n=65 in each group) and 128 
patients were randomized to receive active treatment (n=63) and placebo (n=65), being 
2 patients excluded.  
Demographic characteristics were homogeneous in both groups (Table 1), with more 
women than men in the whole sample (69.35% vs 30.65%) and in both groups and with 
a mean age of 48.29±13.95 years in the active group and 47.72±14.21 years in the 
placebo group (Table 1). 
Parameters recorded at baseline, including vital signs and analytical analyses, were 
comparable in both groups (Table 1). Similar profiles of concomitant and previous 
diseases were recorded in both groups, with similar percentages of patients having 
previous and underlying diseases (72.13% in the active group vs 76.56% in placebo) 
(Table 1).  
Concomitant medications taken during the study period were similar in both groups 
(Table 2).  
Results of adherence showed that all 128 patients included in the analysis were 100% 
complaint with the study treatment.  
Regarding the primary study variable, i.e, safety assessment, in the whole sample, a 
total of 15 and 9 AEs were reported at visits 2 and 3, respectively. At visit 2, 9 AEs 




group, without statistically significant differences in the AE’s prevalence between both 
groups (p=0.1533). At visit 3, the occurrence of AEs decreased, with 4 events (6.67%) 
in the active group and 5 (8.47%) in the placebo group, with statistically significant 
differences between both groups (p=0.0361). 
In the both groups, main reported AEs included gastrointestinal events as abdominal 
and stomach ache, difficulties to evacuate and bloating. In the active group headache 
was also reported, while, in the placebo group, insomnia, agitation and itching were also 
observed. All of them were of mild or moderate intensity and no serious AEs were 
reported during the whole study period. Only gastrointestinal events were considered as 
possibly related to the study treatment. 
Active treatment did not produce relevant changes in clinical signs, without 
statistically significant differences between baseline and visit 3 values. 
Likewise, no statistically significant changes were observed in the analytical 
parameters after active treatment. 
Regarding the primary efficacy variable, i.e., the rate of clinical remission at 4 and 8 
weeks, defined as the disappearance of diarrhea, i.e. 2 or less nonwatery stools 
emissions per day (stool of type 5 or less on the Bristol scale), we observed a 
statistically significant increase in the rate of clinical remissions across the study in the 




76.19% vs 47.69% at visit 3, respectively) (p<0.0001 among visits, Kruskall Wallis test) 
(Figure 2). 
In patients treated with oligo- and poly-saccharides and reticulated protein, the mean 
(± SD) number of stools emitted at days 1, 28 and 56 was 2.91 (± 1.63), 2.43 (± 1.41) 
and 2.25 (± 1.47), respectively. Patients treated with oligo- and poly-saccharides and 
reticulated protein during 28 or 56 days reduced the number of stools emissions 
compared to patients treated with placebo during the same period of time, in a 
statistically significant manner (Student-t test; p=0.031 at day 28 and p=0.001 at day 
56). The mean reduction of stool emissions was 0.53 (CI95%: 0.05 to 1.02 stool 
emissions) at day 28 and 0.84 (CI95%: 0.34 to 1.33 stool emissions) at day 56. A higher 
reduction of stool emissions was observed at longer periods of treatment with oligo- and 
poly-saccharides and reticulated protein: 28 days of treatment reduced the stool 
emissions in a mean average of 0.48 (CI95%: 0.17 to 0.78 stool emissions) compared to 
day 1 (p=0.02; paired-t test), whereas 56 days of treatment reduced the stool emissions a 
mean average of 0.656 (CI95%: 0.29 to1.02 stool emissions) compared to day 1 
(p=0.01). 
In the whole sample, we reported an improvement in the intensity of abdominal pain 
and flatulence measured in a 7-point Likert scale, with significant increases in the 
percentages of patients feeling very much better from visit 2 to visit 3 (8.80% vs 




we also detected a significant improvement in symptoms across the study, with 
statistically significant differences between visit 2 (day 28) and visit 3 (day 56) in the 
abdominal pain (p=0.0167, visit 2 vs visit 3, Mann Whitney test) and flatulence 
assessment (p=0.0373, visit 2 vs visit 3) (Figures 3a and 3b).  
At the end of the study, the percentage of patients with abdominal pain was 
significantly lower in the active group than in the placebo group (0.6% and 58.4% of 
patients, respectively) (p<0.05). The mean average of abdominal pain score was 1.79 
(CI95%: 1.38 to 2.12 score), being this score higher in patients treated with reticulated 
protein and oligo- and poly-saccharides, with a mean (± SD) score of 4.92 (± 0.86), than 
in patients treated with placebo, with a mean (± SD) score of 3.13 (±1.36) (Figure 3a). 
The mean difference was statistically significant (p<0.0001). 
Regarding flatulence, treatment with oligo- and poly-saccharides and reticulated 
protein produced a mean reduction of 0.43 (CI95%: 0.13 to 0.728) in the score reported 
by the patients at the end of the study, being this reduction was statistically significant 
(paired-t test, p=0.005). At the end of the study, the mean average of flatulence score 
was a 1.98 (CI95%: 1.58 to 2.38 score), significantly higher in patients treated with 
oligo- and poly-saccharides and reticulated protein than in patients treated with placebo 
(p<0.0001) (figure 3b). At the end of the study, the percentage of patients with 




patients treated with placebo (0.8% and 63.1% of patients, respectively) (Fisher’s Exact 
test, p<0.05). 
Regarding the punctuation in the IBS QoL questionnaire, we detected a statistically 
significant increase in the quality of life of patients receiving oligo- and poly-
saccharides and reticulated protein from baseline to visit 3 (99.59±23.17 at baseline to 
69.22±24.79 at visit 3, p<0.0001, Mann Whitney test) (Figure 4), while a lower 
improvement in quality of life was detected in the placebo group (94.95±25.62 at 
baseline to 76.94±27.12 at visit 3, p<0.0001, unpaired t test) (Figure 4). In the 
comparison of scores obtained between groups, we detected statistically a significant 
higher improvement in the active group than in the placebo group (p=0.0053, Mann-
Whitney U test). 
Finally, treatment compliance was high in the whole sample (100% at visit 2 and 
99.16% at visit 3).  
 
Discussion 
Nowadays, in a context in which IBS is described as multifactorial with a strong 
psychosocial component, in which many different drugs have been proposed but with 
debatable real benefits,1,12 the use of non-pharmacological strategies, as prebiotics 




In our study, for the first time, we have demonstrated that the combination of a mixture 
of oligo- and poly-saccharides and a reticulated protein is a safe and feasible treatment 
to reduce main symptoms and to improve quality of life in patients with IBS. Both 
ingredients are not absorbed, being effect local on the intestinal mucosa. We consider 
that, since IBS is a multifactorial disease, in which dietary habits and gastrointestinal 
microbiota has a role, we consider that the favorable effects observed are due to the 
synergistic action of both components, acting on the intestinal mucosa (reticulated 
protein) and increasing bifidobacteria counts (mixture of oligo- and poly-saccharides). 
These two effects have been synergistically produced the observed decrease of IBS 
symptoms, such as diarrhea, abdominal pain and flatulence, and the increase of quality 
of life.  
 
These results support the use of the combination versus the use of the components 
alone (reticulated protein and oligo- and poly-saccharides), as reported in previous 
studies where no clear benefits were observed with these or similar compounds.15,28,29 
In a multicenter, randomized, double-blind, placebo-controlled parallel group study 
consisting of a 2-week, in 96 patients with IBS, although symptoms worsened in 
patients with IBS at the onset of treatment with 20 g fructo-oligosaccharides/day, 




Better results were obtained in another comparative, randomized, double-blind study, 
in which participants with IBS symptoms were randomized to receive either 5 g of 
short-chain fructo-oligosaccharides or placebo daily in divided doses. Following six 
weeks of supplementation a statistically significant decrease in symptom scores was 
observed in the group taking fructo-oligosaccharides compared to placebo.15,28 
In our study, the use of a combination of a prebiotic and a film-forming agent can 
provide synergistic effects to regulate the two main conditions of IBS, visceral 
hypersensitivity (which leads to abdominal discomfort or pain) and gastrointestinal 
motor disturbances (leading to diarrhea or constipation),17 by influencing the gut 
microbiota balance (mixture) and the micro-inflammation state of the intestine (protein) 
present in patients with IBS. 
These inulin-type prebiotics are oligo- or polysaccharide long chains comprised 
primarily of linked fructose molecules that are considered to be bifidogenic (stimulating 
the growth of Bifidobacteria and Lactobacilli species), thus promoting specific changes 
in the composition of the gastrointestinal microbiota.15,30-32 
Since the role of the gastrointestinal microbiota in pathogenesis of IBS, and in 
particular the relative lower numbers of bifidobacteria in diarrhoea-predominant IBS, 
has been demonstrated,2,4 the results of our study support the use of the mixture in IBS 
at the studied low doses (1.2 g/day). Our results are in line with other studies,2,33 




in IBS, with some evidence that higher doses may have a negative impact on 
symptoms.2 
Our results support the previous knowledge according which a less diverse and 
unstable community of bacteria is present in IBS and that manipulation of microbiota 
can influence the key symptoms, including abdominal pain and bowel habit and other 
prominent features of IBS.4 
In addition, the favourable results obtained in our study should also be attributed to 
the effect of the reticulated protein, belonging to a new class of agents, which may be 
defined as "film-forming agents" or “mucosal protectors” (also including gelatin 
tannate, gelatin or xyloglucan), which are able to form a protective mucoadhesive film 
in the intestine, reducing inflammation of the wall13,23 (Bueno et al, in preparation). In 
previous in vitro and in vivo studies, we have demonstrated that this type of proteins, 
linked to tannins´ molecules, are able to prevent gut leakiness and subsequent 
inflammation by creating a consistent biobarrier in the intestine13,14 (Bueno et al, in 
preparation). 
We consider that the reticulated protein, acting as intestinal film-forming and 
protective agent, can also contribute to the reduction of characteristic symptoms in 
patients with diarrhea-predominant IBS, thus leading to an improvement of quality of 




Since in diarrhea-predominant IBS, altered intestinal barrier is present and it is 
associated with immune activation and clinical symptoms,34 the use of mucosal 
protectors constitutes new alternatives for a more efficient control of symptoms in 
diarrhea-predominant IBS. 
Of note, for all efficacy variables, we obtained better outcomes at the end of the 
treatment, after 56 days of treatment, than at visit 2, after 28 days. We consider that 
these results support the long term use of the product to produce those intestinal 
changes necessary to decrease IBS symptoms and to increase quality of life of patients.  
 
Overall, the combination of oligo- and poly-saccharides and reticulated protein is a 
safe and feasible option, able to reduce IBS symptoms and increase quality of life in 
patients, thus supporting the inclusion of oligo- and poly-saccharides and reticulated 
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Table 1. Baseline characteristics, anthropometric data, analytical parameters and 







Gender (F / M) n (%) 43 (68.25) / 20 
(31.75) 
45 (69.23) / 20 
(30.77) 
 
Age (years) Mean (SD) 48.29 (13.95) 47.72 (14.21) 
    
Weight (kg) Mean (SD) 69.91 (13.48) 72.27(13.70) 
Height (cm) Mean (SD) 166.00 (7.34) 167 (8.92) 
Temperature (ºC) Mean (SD) 36.50 (0.41) 36.49(0.30) 
Systolic blood pressure (mmHg) Mean (SD) 124.1 (15.16) 124.9 (15.99) 
Diastolic blood pressure (mmHg) Mean (SD) 76.77 (9.85) 76.58 (10.51) 
Heart rate (beats/min) Mean (SD) 71.6 (7.68) 71.8 (8.61) 
    
Analytical parameters Mean (SD)   




 Glucose (mg/dl)  96.66 (26.93) 95.33 (17.07) 
 Creatinine (mg/dl)  0.87 (0.18) 0.86 (0.22) 
 AST (U/l)  24.48 (10) 22.40 (7.71) 
 ALT (U/l)  28.26 (13.89) 25.75 (14.01) 
 Gamma-GT (U/l)  32.66 (25.46) 32.20 (20.62) 
 Alkaline phosphatase (U/l)  115.9 (62.56) 113.70 (55.75) 
 Erythrocyte sedimentation rate 
(mm/h) 
 13.13 (10.20) 16.67 (17.06) 
     
Concomitant and previous diseases n (%)   
 Cardiovascular diseases  7 (11.11) 6 (9.23) 
 Endocrine diseases  4 (6.35) 2 (3.07) 
 Gastrointestinal diseases  3 (4.76) 7 (10.67) 
 Hepatic diseases  2 (3.17) 3 (4.61) 
 Musculoskeletal diseases  1 (1.59) 2 (3.07) 
 Dermatological diseases  1 (1.59) -- 
 Respiratory diseases  1 (1.59) -- 
 Urinary disorders  1 (1.59) 2 (3.07) 





Table 2. Concomitant medications taken during the study period 
 
Group Medication (active substance) Duration of 
treatment during 
the study period 
Active 
group 
metoprolol/enalapril 56 days 
 
sucralfate 1 day 
 
oral combined contraceptives 56 days 
 
perindopril/indapamide 56 days 
 
amlopidine/metoprolol/ginko biloba/diosmine 56 days 
 
atenolol/glycazide/insulin 56 days 
 





levothyroxine/indapamide/enalapril 56 days 
 omeprazol/ramipril 56 days 
 
 
metoprolol/enalapril 56 days 
 
 
oral combined contraceptives 56 days 
 
 






























Figure 2. Rate of clinical remission during the study period (defined as defined as the 
disappearance of diarrhea, i.e. 2 or less nonwatery stools emissions per day (stool of 










Figure 3. Evolution of abdominal pain and flatulence according to a 7-point Likert 
scale. a) Evolution of abdominal pain in active and placebo groups from baseline to visit 
3 based on a 7-point Likert scale (7 = very much better, 6 = much better, 5 = somewhat 
better, 4 = same, 3 = somewhat worse, 2 = much worse, 1 = very much worse). b) 
Evolution of flatulence in active and placebo groups from baseline to visit 3 based on a 
7-point Likert scale (7 = very much better, 6 = much better, 5 = somewhat better, 4 = 


















Figure 4. Scores obtained in the IBS QoL questionnaire from baseline to visit 3. The 
IBS QoL questionnaire is a 34-item measure constructed specifically to assess the 
subjective well-being of patients with IBS, including eight dimensions (dysphoria, 
interference with activity, body image, health worry, food avoidance, social reaction, 
sexual dysfunction, and relationships). Each item is scored on a five-point scale (1 = not 
at all, 5 = a great deal). To facilitate score interpretation, the summed total score is 
transformed to a zero to 100 scale ranging from zero (maximum quality of life) to 100 
(minimum quality of life). 
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